Fanconi Cancer Foundation

What Fanconi Cancer Foundation does

Fanconi Cancer Foundation (FCF), a 501(c)(3) nonprofit headquartered in Eugene, Oregon, funds research and provides community support for individuals affected by Fanconi anemia (FA) and FA-associated cancers. Founded in 1989 by Lynn and David Frohnmayer after three of their daughters were diagnosed with FA, FCF has directed more than $33 million to 260+ research projects worldwide, contributed to the identification of 23 FA-related genes, and is credited with helping double the life expectancy of FA patients over the past three decades. Its current mission centers on cancer — the leading unsolved mortality driver in FA — through programs covering cancer prevention, early detection, treatment, and gene therapy research.

The foundation operates an interconnected portfolio of research, clinical, and community programs. Research infrastructure includes the Fanconi Anemia Cancer Consortium (founded 2021 with University of British Columbia, University of Düsseldorf, NIH, and Rockefeller University), the Patient Registry launched with NORD in 2019, the Fanconi Anemia Research Materials (FARM) repository at Oregon Health and Science University, the Virtual Tumor Board of multi-specialty oncology physicians, and the Global Fanconi Anemia Brush Biopsy (FABB) program for non-invasive head and neck cancer screening. Community-facing programs include the annual Scientific Symposium, FA Family Retreat at The Painted Turtle, Retreat for Adults with FA, mental health support via Give An Hour, caregiver and grief support, FA Clinical Care Guidelines, and travel scholarships. Recent product launches include the FCF-AACR NextGen Grant for Transformative Cancer Research (April 2024) and an FDA Externally-Led Patient-Focused Drug Development meeting scheduled for October 2026.

FCF is financed entirely by donations, grants, and fundraising events rather than fees for service. Annual program expenditure totals roughly $3.96 million (Research Initiatives $1.64M, Community Support $1.36M, Fundraising $0.40M, Administration $0.57M) drawn from individual donors, major family foundations such as the Phil and Penny Knight initiative ($10 million over 10 years), recurring giving clubs, employer matching, estate and stock gifts, donor-advised funds, and community fundraisers. Customer/mission segments are Individuals with FA, FA Family Members and Caregivers (both primary), FA Researchers and Clinicians, and Donors and Supporters. The organization operates globally — funding research in North America, Europe (Germany, France, Netherlands, UK), and Mexico — and partnerships span Stand Up To Cancer, AACR, NORD, OHSU, Rocket Pharmaceuticals, IQVIA, Cincinnati Children's Hospital, and Stanford Children's Hospital.

Name

Fanconi Cancer Foundation

Legal name

Fanconi Cancer Foundation

Website

https://fanconi.org

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

11–50 employees

Short description

Fanconi Cancer Foundation is a Eugene, Oregon-based 501(c)(3) nonprofit founded in 1989 that funds Fanconi anemia (FA) and FA-associated cancer research and provides clinical, family, and mental health support to FA patients and caregivers worldwide.

Ownership category

akta.pro rank

Product category

Health Research Nonprofit

NAICS

Voluntary Health Organizations (813212)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

Keywords

• Rare disease research
• Cancer research funding
• Patient advocacy services
• Fanconi anemia support
• Nonprofit health foundation

Headquarters

HQ city

Eugene

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Others, Personnel, Operations, Marketing or Sales

Revenue model

1. Individual Donations: Direct donations from individuals supporting FA research and family support programs.
2. Monthly Giving Club (FAM Support Club): Recurring monthly donations from supporters providing continued support for FCF operations and planning.
3. Memorial and Tribute Gifts: Donations made in memory of loved ones affected by FA, often through dedicated memorial pages.
4. Employer Matching Gifts: Corporate programs that match employee donations to FCF, doubling individual contributions.
5. Estate Giving and Legacy Gifts: Gifts through wills, living trusts, life insurance, retirement plans, or real estate that ensure FCF's future mission continues.
6. Stock Gifts: Donations of appreciated stocks or mutual funds providing income tax deductions while avoiding capital gains taxes.
7. Retirement Fund Gifts: Gifts from IRA, 401(k), 403(b), or other tax-deferred retirement plans with potential tax savings.
8. Donor-Advised Funds: Gifts from Donor-Advised Funds allowing individuals and families to make charitable contributions and recommend grants over time.
9. Foundation Grants: Major grants from foundations such as Phil and Penny Knight ($10 million over 10 years), KATA Foundation ($3.1 million raised), and Rice Family ($100,000 per year for 3 years).
10. Fundraising Events: Community-driven fundraisers including Endure for a Cure challenges, FA Awareness Month in May, Giving Tuesday campaigns, and DIY fundraisers.

Go-to-market motion1 record

Distribution channels7 records

Marketing channels8 records

Core offering

Fanconi Cancer Foundation funds Fanconi anemia (FA) and FA-related cancer research, operates the FA Patient Registry and Virtual Tumor Board for clinical support, and delivers community programs including the FA Family Retreat and Scientific Symposium. It advances early cancer detection through the Global Brush Biopsy Program and the Fanconi Anemia Cancer Consortium, while providing psychosocial, mental health, and educational support free of charge to FA patients and families worldwide.

Product overview

Fanconi Cancer Foundation (FCF) is a nonprofit patient advocacy organization offering a portfolio of interconnected research, support, and education programs. The core offerings include: the FA Patient Registry (in partnership with NORD) for collecting disease progression data; the Virtual Tumor Board connecting patients with oncology experts; the Global Brush Biopsy Program for early cancer detection; and the Fanconi Anemia Cancer Consortium coordinating research across four major institutions. Community support programs include the FA Family Retreat at The Painted Turtle, Retreat for Adults with FA, and Scientific Symposium (held jointly). Mental health support is provided through partnerships with Give An Hour. Research is advanced through grant programs including the FARF/SU2C partnership, Joel Walker Cancer Ideas Lab, and the new FCF-AACR NextGen Grant. These programs work together to advance FA research, provide community support, and improve outcomes for FA patients and families.

Differentiator

Problem solved

Functional benefit

Products and services

• FA Patient Registry A patient registry specifically for Fanconi anemia, launched in partnership with the National Organization for Rare Diseases (NORD), consisting of patient-directed surveys that collect information about disease progression and experiences of individuals living with FA to help researchers direct studies toward better treatments.
• Virtual Tumor Board A panel of physicians from various oncology fields who volunteer to discuss complex FA solid tumor cases and offer treatment guidance to treating physicians managing FA patients with cancer.
• Global Fanconi Anemia Brush Biopsy (FABB) Program A screening program demonstrating that oral brush biopsies are an effective and safe way to screen people with FA for head and neck cancer, detecting early precursor lesions at a non-invasive stage when surgical removal is highly successful.
• FA Family Retreat An annual camp-style retreat held at The Painted Turtle offering connection, educational sessions, expert consultations, and psychosocial support for FA families. Provided free of charge.
• Retreat for Adults with FA An annual retreat for individuals with FA ages 18+ to meet peers, learn about medical and research updates, attend support sessions, and participate in voluntary research studies.
• FA Scientific Symposium An annual scientific symposium bringing together prominent and aspiring FA researchers, clinicians, and stakeholders to share latest updates in research and treatment of Fanconi anemia.
• Fanconi Anemia Cancer Consortium (FACC) A research consortium founded in 2021 consisting of researchers from University of British Columbia, University of Düsseldorf, NIH, and Rockefeller University focused on improving patient care for early detection, screening, and treatment of FA cancers.
• Fanconi Anemia Research Materials (FARM) Repository A collaboration between FARF and Oregon Health and Science University that stores FA antibodies, human and mouse FA fibroblasts, and cancer cell lines in a centralized repository for scientist research requests.
• EL-PFDD Meeting An Externally-Led Patient-Focused Drug Development meeting to gather input directly from people affected by Fanconi anemia and share with the FDA, centered on lived experience including daily challenges, treatment experiences, and quality of life.
• FCF Research Grant Programs Grant programs funding research in cancer prevention, detection, treatment and awareness, gene editing and gene therapy, preclinical models, clinical trials, and quality of life improvements.
• FA Family Quality of Life Study A qualitative study conducted with Rocket Pharmaceuticals, IQVIA, and patient advocates, speaking with 25 FA families including children, teens, adults, and caregivers about daily life impacts including physical, emotional, social, and financial effects.
• Mental Health Support Programs Psychosocial support services including caregiver support, patient advocacy, grief support, and 1:1 psychosocial support. Partnership with Give An Hour provides no-cost mental health care and education for the FA community.
• Fanconi Anemia Clinical Care Guidelines Clinical guidelines developed for FA care including guidance on Fanconi Anemia Neurological Syndrome (FANS). Provides standards for diagnosis and treatment of FA patients.
• Travel Scholarship Program A scholarship assistance program supporting families and adults with FA with travel expenses for attending retreats and events.

Quantifiable outcome

• Life expectancy more than doubled for FA patients
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Give An Hour (GAH)coreStrategic or Co-development Partner · 1 January 2025FCF partnered with Give An Hour, a national nonprofit dedicated to expanding access to no-cost mental health care and education, to advance mental health support for the FA community.
• Stand Up to Cancer (SU2C)coreStrategic or Co-development Partner · 1 January 2021FARF partnered with SU2C to facilitate collaborations between FA researchers and cancer experts. This partnership includes four organizations (American Head and Neck Society, Head and Neck Cancer Alliance, Farrah Fawcett Foundation) and formed a head and neck cancer research team led by Dr. Agata Smorgorzewska from Rockefeller University.
• American Association for Cancer Research (AACR)coreStrategic or Co-development Partner · 1 January 2021FCF partnered with AACR to launch the FCF-AACR NextGen Grant for Transformative Cancer Research, a flagship funding opportunity supporting innovative cancer research.
• National Organization for Rare Diseases (NORD)coreStrategic or Co-development Partner · 1 January 2019FCF and NORD launched a patient registry specifically for Fanconi anemia, collecting patient-directed surveys on disease progression and experiences to help researchers direct studies toward better treatments.
• Fanconi Anemia Cancer Consortium (FACC) InstitutionscoreStrategic or Co-development PartnerFACC consists of researchers from University of British Columbia, University of Düsseldorf, National Institutes of Health (NIH), and Rockefeller University working on collaborative projects focused on early detection, screening, and treatment of FA cancers.
• Oregon Health and Science University (OHSU)coreStrategic or Co-development PartnerOHSU collaborates with FARF on the Fanconi Anemia Research Materials (FARM) repository, storing FA antibodies, cell lines, and cancer cells for researcher access.
• FA Europe Network / Fanconi Hope / Dutch FA Support GroupcoreStrategic or Co-development PartnerFCF provided international grant support to FA Europe Network, which hosted its inaugural pan-European scientific meeting in Paris in May 2024, bringing together 92 participants from 12 countries.
• Double the DonationminorChannel Partner/ Reseller/ DistributorFCF partners with Double the Donation to provide employer matching gift program information to donors, helping double their support without additional cost.
• The Painted TurtlecoreStrategic or Co-development PartnerFCF partners with The Painted Turtle to host the annual FA Family Retreat, a camp providing year-round, life-changing experiences for children with chronic and life-threatening illnesses, completely free of charge for FA families.
• Cincinnati Children's HospitalcoreStrategic or Co-development PartnerKey FA treatment center partner, home to the Virtual Tumor Board and Dr. Stella Davies, Director of the Division of Bone Marrow Transplantation and Immune Deficiency.
• National Institutes of Health (NIH)coreStrategic or Co-development PartnerNIH partnership includes cancer screening studies, the Fanconi Anemia Cancer Consortium, and clinical programs for early cancer detection in FA patients.
• Rocket Pharmaceuticals, Inc.coreStrategic or Co-development PartnerRocket Pharma partnered with FCF, IQVIA, and patient advocates to conduct qualitative research studies on the lived experiences of FA patients and families, interviewing 25 families about quality of life impacts.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• National Childhood Cancer Foundation (CureSearch): Nonprofit funding childhood cancer research and supporting families. Tangentially comparable through pediatric cancer focus and research grantmaking, though broader and less disease-specific than FCF.
• Rally Foundation for Childhood Cancer Research: Childhood cancer-focused nonprofit funding young investigators and research; overlaps with FCF's pediatric cancer research funding but at a broader category level rather than a single rare disease.

Direct peers

• Muscular Dystrophy Association (MDA): Disease-focused nonprofit funding research and delivering patient/family support across neuromuscular diseases. Comparable combination of research funding, clinical care networks, and family services.
• National Organization for Rare Disorders (NORD): Federation of rare-disease patient organizations; FCF partners with NORD to operate the FA Patient Registry. NORD's umbrella model of supporting disease-specific foundations makes it the closest direct operational peer.
• Cystic Fibrosis Foundation: Disease-specific nonprofit that funds a vertically integrated research-to-therapeutic pipeline and maintains a patient registry. Highly analogous model to FCF, but in a more prevalent genetic disease.
• Aplastic Anemia & MDS International Foundation: Nonprofit supporting patients with bone marrow failure and related blood disorders, including Fanconi anemia overlaps. Highly comparable mission around bone marrow failure, transplant support, and rare hematology research.
• Parent Project Muscular Dystrophy (PPMD): Parent-led rare-disease foundation funding research, clinical care guidelines, and patient registries for Duchenne muscular dystrophy. Mirrors FCF's family-driven origin and integrated research-plus-support model.
• The A-T Children's Project: Family-founded nonprofit funding research and supporting families affected by Ataxia-Telangiectasia, another rare DNA-repair disorder. Closely analogous mission, scale, and DNA-repair pathway connection to FA.

Broad incumbents

• American Cancer Society: Large incumbent cancer-focused nonprofit that funds broad research and patient support programs. Overlaps with FCF's cancer research portfolio, especially head and neck cancer, but at a vastly different scale and scope.
• St. Jude Children's Research Hospital / ALSAC: Major pediatric cancer research and treatment institution with associated fundraising organization. Comparable in serving pediatric oncology patients and funding research, but with in-house clinical and research operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/todosconfanconi

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fanconi Cancer Foundation